Recently published meta-analysis (May 2024) combining all 4 large long-running randomized controlled trials that tested a traditional Mediterranean diet verses heart disease.
Large long-running RCT’s are the highest quality evidence in medicine. They are at the very top of the evidence hierarchy because they directly prove causality.
Summary of results for the Mediterranean diet:
(verses control diets similar to American Heart Association recommendations at the time)
- MACE events reduced by 48%
- Heart attacks reduced by 38%
- Strokes reduced by 36%
- Cardiovascular mortality reduced by 46%
The 4 RCT’s included in the meta-analysis were: the Lyon Diet Heart Study, the Indo-Mediterranean Diet Heart Study, the PREDIMED Study, and the recent CORDIOPREV Study.
You can read more about the results from the individual randomized controlled trials below:
Lyon Heart Study:
PREDIMED:
CORDIOPREV:
Indo-Mediterranean Diet Heart Study:
- The Lancet article (The Lancet)
Quoted:
“Our analysis incorporated four RCTs involving a total of 10,054 participants, with an average age of 57 years and a mean follow-up duration ranging from 2 to 7 years. In our pooled analysis, the composite endpoint of major adverse cardiovascular events (MACE) demonstrated a statistically significant reduction in incidence in participants on MedDiet versus control diet with an OR of 0.52 (95 % CI: 0.32 to 0.84, p = 0.008; I2 = 87 %). Additionally, our study revealed a notable decrease in the incidence of cardiovascular events, both myocardial infarction (MI) and stroke in the the MedDiet group, with an OR of 0.62 (95 % CI: 0.41 to 0.92, p = 0.02; I2 = 56 %) and 0.63 (95 % CI: 0.48 to 0.87, p = 0.002; I2 = 0 %), respectively. However, no statistically significant change in the rate of revascularization was observed, with an OR of 0.74 (95 % CI: 0.30 to 1.27, p = 0.06; I2 = 16 %). Concerning mortality rates, MedDiet significantly reduced the risk of cardiovascular death with an OR of 0.54 (95 % CI: 0.31 to 0.94, p = 0.03; I2 = 55 %), while no significant change was noted in all-cause mortality, with an OR of 0.77 (95 % CI: 0.51 to 1.15, p = 0.20; I2 = 58 %).”
“MedDiet serves as an effective intervention for both primary and secondary prevention of CVD, demonstrating a substantial and long-term impact in reducing the incidence of MACE, MI, stroke, and cardiovascular-related mortality while showing no observed effect on all-cause mortality.”
#mediterraneanHD #lyonHD #predimedHD #cordioprevHD #indomediterraneanHD #mediterraneanrctHD
